Loading clinical trials...
Loading clinical trials...
Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL) - (Optimizing Acute Stress Reaction Interventions With TNX-102 SL - OASIS)
Conditions
Interventions
Cyclobenzaprine HCl
Placebo
Locations
9
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Indiana University
Indianapolis, Indiana, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
Washington University in St. Louis
St Louis, Missouri, United States
Cooper University Health System
Camden, New Jersey, United States
The Ohio State University
Columbus, Ohio, United States
Start Date
March 25, 2025
Primary Completion Date
September 1, 2026
Completion Date
September 1, 2026
Last Updated
April 13, 2026
NCT07069478
NCT07497009
NCT04924166
NCT07163468
NCT05452460
NCT03954522
Lead Sponsor
University of North Carolina, Chapel Hill
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions